Renu Chandrasekaran

The paper develops macrocyclic peptides that target HAP40, enabling the study of HTT-HAP40 interactions and their role in Huntington's disease.

The paper develops and validates novel monoclonal antibodies targeting the C-terminal HEAT domain of huntingtin, showing they detect full-length HTT regardless of polyglutamine length or HAP40 interaction.

The paper develops a chemical probe targeting the USP16 zinc-finger ubiquitin-binding domain and evaluates its selectivity and activity in cellular assays.

The paper identifies a small molecule ligand for the HTT-HAP40 complex using AS-MS and validates its binding through multiple techniques, highlighting a druggable interface for HD therapeutics.

This paper identifies and characterizes high-affinity, selective macrocyclic peptide ligands for Huntingtin, enabling structural and functional studies of HTT and its complex with HAP40.

This study investigates challenges in mHTT quantification in CSF, showing that absolute quantitation is unreliable due to protein complexity and recommends relative quantitation instead.

This study identifies huntingtin as an RNA-binding protein that interacts with G-rich RNA sequences, including those in the NEAT1 paraspeckle lncRNA.